Cardiovascular Considerations In Antipsychotic Use: An Editorial

Cardiovascular Considerations In Antipsychotic Use: An Editorial

-

Bibliographic Details
Main Authors:	Alireza Hasanzadeh, Saeed Nateghi
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2023-12-01
Series:	Case Reports in Clinical Practice
Subjects:	-
Online Access:	https://crcp.tums.ac.ir/index.php/crcp/article/view/900

Similar Items

Clinical considerations in selecting and using atypical antipsychotics
by: Haupt Dan
Published: (2006-02-01)

Antipsychotic-induced immune dysfunction: A consideration for COVID-19 risk
by: Meghan May, et al.
Published: (2020-07-01)

Considerations about the Brazilian Journal of Cardiovascular Surgery editorial profile
by: Domingo M. Braile

Cardiovascular and Metabolic Adverse Reactions Associated with the Use of Antipsychotic Drugs: A Narrative Review
by: Priya C Patel, et al.
Published: (2022-01-01)

Cardiovascular risk screening of patients with serious mental illness or use of antipsychotics in family practice
by: Kirsti M. Jakobs, et al.
Published: (2020-07-01)

Use of antipsychotics with tamoxifen
by: H. Ghabi, et al.
Published: (2021-04-01)

Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review
by: Amber N. Edinoff, et al.
Published: (2022-03-01)

Comparing Cardiovascular Complications of Poisoned Patients with Antipsychotics and Antidepressants with or without Benzodiazepines
by: Ahmad Yaraghi, et al.
Published: (2019-02-01)

Atypical antipsychotics, more than just an antipsychotic
by: Hiram Tendilla-Beltran, et al.
Published: (2020-01-01)

Evaluation of stroke risk associated with the use of typical or atypical antipsychotics among patients with cardiovascular diseases
by: Meng-Ting Wang, et al.
Published: (2015-01-01)

Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia
by: Said, Mas Ayu, et al.
Published: (2012)

Antipsychotics and Risks of Cardiovascular and Cerebrovascular Diseases and Mortality in Dwelling Community Older Adults
by: Sylvie Perreault, et al.
Published: (2024-01-01)

Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach
by: Shulman M, et al.
Published: (2014-10-01)

Adiponectin Is Related to Cardiovascular Risk in Severe Mental Illness Independent of Antipsychotic Treatment
by: Elina J. Reponen, et al.
Published: (2021-05-01)

Metabolic syndrome and the use of antipsychotics
by: Mavreas Venetsanos, et al.
Published: (2006-02-01)

Clinical Considerations for Cannabis Use and Cardiovascular Health
by: Ruba Sajdeya, et al.
Published: (2022-09-01)

Cardiovascular Risk of Concomitant Use of Atypical Antipsychotics and Stimulants Among Commercially Insured Youth in the United States
by: Chengchen Zhang, et al.
Published: (2021-04-01)

Oxidation of Antipsychotics
by: Natalia A. Shnayder, et al.
Published: (2022-05-01)

Antipsychotics and rashes
by: Jessica Lin
Published: (2018-11-01)

Atypical antipsychotics:
by: Claudia Aparecida Avelar Ferreira, et al.
Published: (2015-10-01)

Cardiovascular considerations in tuberous sclerosis
by: Joanna Kohut, et al.
Published: (2017-06-01)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
by: Correll Christoph, et al.
Published: (2005-05-01)

Antipsychotics use in dementia: How safe are they?
by: C. Lopes
Published: (2021-04-01)

Antipsychotics use in the community of Thessaloniki, Greece
by: Papaioannidou Paraskevi, et al.
Published: (2018-01-01)

Editorial: Non-Invasive Measures of Cardiovascular Function and Health: Special Considerations for Assessing Lifestyle Behaviours
by: Simon Fryer, et al.
Published: (2022-04-01)

Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations
by: Orietta Zaniolo, et al.
Published: (2019-02-01)

Antipsychotic-induced Hyperprolactinemia
by: Suheyla Dogan Bulut, et al.
Published: (2015-06-01)

Antipsychotics: 70 Years
by: Giovanni Lentini, et al.
Published: (2023-11-01)

Intellectual disability and antipsychotics
by: I. Cuevas Iñiguez, et al.
Published: (2021-04-01)

Antipsychotic medication and the elderly
by: D. Jardak, et al.
Published: (2021-04-01)

antipsychotics and metabolic syndrome
by: R. Jomli, et al.
Published: (2022-06-01)

Diabetes and atypical antipsychotics
by: Stathaki Maria, et al.
Published: (2008-04-01)

Nutritional Considerations of Cardiovascular Diseases and Treatments
by: Marko Boban, et al.
Published: (2019-03-01)

Breast Cancer Treatment and Cardiovascular Considerations
by: Maryam Mehrpooya, et al.
Published: (2018-03-01)

Cardiovascular Considerations in COVID-19 Pandemic
by: Razieh Parizad, et al.
Published: (2021-01-01)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
by: Sang Won Jeon, et al.
Published: (2017-10-01)

Identification of Antipsychotic Side Effects with Glassgow Antipsychotic Side-Effect Scale (GASS)
by: Dita Hasni, et al.
Published: (2020-08-01)

Clinical use of second-generation antipsychotics in children
by: Kirsi Kakko, et al.
Published: (2017-10-01)

Influence of the use of atypical antipsychotics in metabolic syndrome
by: P Doménech-Matamoros
Published: (2020-07-01)

Antipsychotic use and psychiatric disorders in COVID-19
by: Augusto Ferraris, et al.
Published: (2021-02-01)